Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease
Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…Factors associated with occurrence of motor complications among Parkinson’s disease patients with levodopa treatment in Estonia
Objective: To identify the factors associated with the occurrence of motor complications among patients with Parkinson’s disease (PD) who receive levodopa treatment. Background: Levodopa is the…A long-term study on effectiveness of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients
Objective: To present the design of and baseline patient characteristics from an ongoing global study assessing the long-term effectiveness of levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa…An Unusual Cause of Rhabdomyolysis in Parkinson’s disease
Objective: To describe an unusual cause of rhabdomyolysis in patient with advanced Parkinson’s disease (PD) treated with levodopa. Background: Rhabdomyolysis is a serious and life-threatening…Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.
Objective: To define variation in L-dopa response in recent onset PD. Background: L-Dopa responsiveness is a defining feature of Parkinson’s disease (PD), but the degree…Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study
Objective: Evaluate the efficacy and safety of IPX203 vs. immediate-release (IR) carbidopa-levodopa (CD-LD) and vs. extended-release (ER) CD-LD (IPX066, RYTARY®) in patients with advanced Parkinson’s…Parkinsonism in the very old – A clinicopathological study
Objective: To identify, spectrum of Parkinson variants, clinical features and course of disease in age > 80 year onset cases. Background: Old age is the…Interim Results of an Ongoing Open-label Safety Study of ADS-5102 (amantadine hydrochloride) Extended-Release Capsules for Treatment of Levodopa-Induced Dyskinesia (LID) (EASE LID 2 Study)
Objective: Characterize the long-term safety and tolerability of 340 mg of ADS-5102 administered once daily at bedtime, for the treatment of LID in Parkinson’s disease…Post-hoc analyses of the recommended starting dose for Rytary based on “off” time
Objective: To determine whether correcting for “off” time duration improves the selection of the final LD dose when converting to extended-release carbidopa-levodopa capsules (ER CD-LD,…Compulsive sexual behaviour in Parkinson’s disease is associated with higher doses of levodopa
Objective: To assess whether compulsive sexual behaviour in individuals with PD is associated with higher doses of levodopa. Background: The lifetime prevalence of compulsive sexual behaviour…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 62
- Next Page »